Current Research
Find out more about taking part in one of our studies
Find out more about taking part in an intervention treatment trial where you may receive a new treatment being tested for T1D. We also have information on monitoring trials where data is collected but there is no intervention/treatment and also information on screening for T1D. Screening studies are also available which can identify people who may be at risk of developing T1D
Treatment Trials
Baricade-delay Study
✅ Currently recruiting
A Phase 3, Double-Blind, Randomised, Placebo-Controlled study of Baricitinib to delay Stage 3 Type 1 Diabetes in at-risk participants aged ≥1 to <36 years.
Safeguard Study
✅ Currently recruiting
A Phase 2b, Randomised, Double-Blind, Placebo-Controlled, Parallel-Arm Dose Finding Study Evaluating the Efficacy and Safety of SAB-142 for Delaying the Progression of Type 1 Diabetes (T1D) in Patients with Stage 3 New Onset of Type 1 Diabetes (NOT1D)
Beta-Preserve
✅ Currently recruiting
A randomised, double-blind, Phase 3 study to investigate efficacy and safety of teplizumab compared with placebo in participants 1 to 25 years of age with recently diagnosed Stage 3 Type 1 Diabetes (T1D)
SMART
Currently running
Treg-sparing co-stimulation blockade: testing a novel method for monitoring an immunosuppression strategy in people with Type 1 diabetes.
Monitoring Studies
Would you like to be involved in studies where you have more monitoring, so that researchers can find out more about type 1 diabetes?
UK Islet Autoantibody Registry
The UKIAb Registry is a list of children, young people and adults who have markers in their blood (islet autoantibodies) that indicate they are at risk of developing type 1 diabetes (T1D).
ADDRESS 2
A research project for children and adults aged 1 or older and newly diagnosed with type 1 diabetes (within the last 6 months), to collect information about their diabetes, and inform them about other opportunities to take part in type 1 diabetes research. Siblings can help too.
ARAD – At Risk of Autoimmune Diabetes
The ARAD study is open to both adults and children who have previously tested positive for one or more islet autoantibody risk markers for developing type 1 diabetes in the future. The study offers follow-up monitoring of autoantibody markers using home collection sample kits.
Screening
Type 1 diabetes risk in adults (T1DRA)
Research Study screening for risk of type 1 diabetes in adults aged 18-70 years.
ELSA Study
The ELSA study is screening children (age 2-15) and young adults (age 16-17) for type 1 diabetes.
Closed Trials
FABULINUS
Recruitment closed until further notice
The FABULINUS Study is testing an investigational study drug in people recently diagnosed with type 1 diabetes (T1D). Our goal is to see if the investigational study drug can help people with T1D to better manage their glucose levels.
INNODIA – People at Increased Risk
Recruitment closed
A study to identify people who are at increased risk of developing T1D and monitor them for two years to see who progresses to T1D.
T1D-Plus
Recruitment closed
An adaptive platform trial by INNODIA – A randomised, adaptive, open label, parallel group, multi-centre platform trial in adults with newly diagnosed type 1 diabetes.
Ver-A-T1D Study
Recruitment closed
A randomised, double-blind, placebo controlled, parallel group, multi-centre trial in adult subjects with newly diagnosed type 1 diabetes mellitus investigating the effect of Verapamil SR on preservation of beta-cell function (Ver-A-T1D)
EXTOD Immune
Recruitment closed
Can a remotely monitored, home-based exercise intervention for individuals with type-one diabetes reduce immune driven disease activity? (EXTOD-Immune)
MELD-ATG Trial
Recruitment closed
Trial of a new medication in people with 1 diabetes aged 5-25. Screening visit to be conducted within 9 weeks of diagnosis.
IMPACT Study
Recruitment closed
Trial of a new medication in people with 1 diabetes aged 18-44. Screening visit to be conducted within 9 weeks of diagnosis.
CFZ533X2207 Trial
Recruitment closed
Study of safety and efficacy of CFZ533 in children and young adults with new onset type 1 diabetes.
DROPLeT
Recruitment closed
Remote study investigating the progression of Type 1 diabetes in adults (18 years and over) within 120 days of diagnosis and insulin treated.
INNODIA
Recruitment closed
A project throughout Europe which collects blood samples and data from newly diagnosed patients between 1 and 45 years who have been diagnosed with type 1 diabetes within the previous 6 weeks and their first degree relatives (brothers, sisters, parents or children).
PROTECT Study
Recruitment closed
The PROTECT Study is testing how well an investigational medicine works in children and adolescents with Type 1 diabetes (T1D).
Interleukin-2 Therapy of Autoimmunity in Diabetes (ITAD)
Recruitment closed
ITAD is a multicentre, randomised, double-blind, placebo-controlled clinical trial of to see if a drug called aldesleukin, can preserve insulin production in children and young adults recently diagnosed with type 1 diabetes.
Ustekinumab in adolescents with new onset type 1 diabetes
Recruitment closed
Trial of a new medication in 12-18 year olds with Type 1 diabetes within 100 days of diagnosis
Research study for people with Type 1 Diabetes: EXALT
Recruitment closed
The main purpose of this study is to assess the safety of three different doses of an investigational drug in patients who have been recently diagnosed with type 1 diabetes.
The Effect of Abatacept on the Immune System in Type 1 Diabetes
Recruitment closed
This study aims to gain a better understanding of the immune processes that lead to the destruction of insulin producing beta cells.
The Effect of Anti-IL-21 and Liraglutide in Newly Diagnosed Type 1 Diabetes
Recruitment closed
This study will investigate if a new drug Anti-IL-21 when given together with another drug marketed for type 2 diabetes called liraglutide can preserve the beta cells in subjects diagnosed with type 1 diabetes.
Moving towards insulin-free T1D